205114-17-6 Usage
General Description
Methyl 3-bromoquinoline-6-carboxylate is a chemical compound with the molecular formula C11H8BrNO2. It is a derivative of quinoline, a heterocyclic aromatic compound commonly found in natural products and pharmaceutical drugs. This chemical is commonly used as an intermediate in the synthesis of various pharmaceutical compounds and other organic molecules. Its structure contains a 3-bromoquinoline core with a carboxylate ester group, making it a versatile building block for the construction of complex organic molecules. Methyl 3-bromoquinoline-6-carboxylate is widely used in organic synthesis and medicinal chemistry research and is an important tool for the development of new pharmaceuticals and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 205114-17-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,1,1 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 205114-17:
(8*2)+(7*0)+(6*5)+(5*1)+(4*1)+(3*4)+(2*1)+(1*7)=76
76 % 10 = 6
So 205114-17-6 is a valid CAS Registry Number.
205114-17-6Relevant articles and documents
3. 4 - dihydro - 1H - benzo [c] [1, 2] oxa boric acid compound or a pharmaceutically acceptable salt thereof and its preparation and use
-
Paragraph 0214-0216, (2017/08/14)
The invention relates to 3,4-dihydro-1H-benzo[c][1,2]oxaboric acid compounds or pharmaceutically acceptable salts thereof, a preparation method of the compounds and application of the compounds and the salts. Concretely, the invention relates to the compound with the general formula (I) and the pharmaceutically acceptable salts, and the preparation method of the compounds. The invention also relates to a pharmaceutical composition containing the compounds or the pharmaceutically acceptable salts as a receptor tyrosine kinase inhibitor, especially as a c-Met inhibitor. The invention also relates to application of the compounds or the pharmaceutical composition to prepare medicines for preventing and/or treating diseases related to c-Met abnormity. The compounds have obvious propagation inhibition activity on SNU-5 cells, and have obvious inhibition effect on c-Met kinases activity.
